Across the UK, pub bells will ring early for the final time this Wednesday as part of a new campaign by Greene King and Macmillan Cancer Support ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

But other possible nuclear medicine treatment options, including radiopharmaceuticals, are in a state of flux in Australia as groundbreaking medical research undertaken here goes offshore to Europe or ...

Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

Maurice Blake wants to raise awareness of prostate cancer and health inequalities [BBC] Three years ago, Maurice Blake was diagnosed with prostate cancer. "I didn't have any of the traditional ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...